Insulin therapy in patients with type 2 diabetes mellitus: Treatment to target fasting and postprandial blood glucose levels

Insulin

Volumn 1, Issue 4, 2006, Pages 158-165

  Raccah, Denis ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

fasting blood glucose; glycemic control; insulin detemir; insulin glargine; prandial insulin; type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DETERIORATION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEAR; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PRACTICE GUIDELINE; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN;

EID: 33845900000     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(06)80036-9     Document Type: Article

References (52)

1. McAulay V., and Frier B.M. Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin Phormocother. 4 (2003) 1141-1156
2. Gerich J.E. Physiology of glucose homeostasis. Diabetes Obes Metob. 2 (2000) 345-350
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
5. Mayfield J.A., and White R.D. Insulin therapy for type 2 diabetes: Rescue, augmentation, and replacement of beta-cell function [published correction appears in Am Fam Physician. 2004;70: 2079-2080]. Am Fam Physician 70 (2004) 489-500
6. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310 (1995) 83-88
7. Wright A., Burden A.C., Paisey R.B., et al., UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57) [published correction appears in Diabetes Care. 2002;25:1268]. Diabetes Care 25 (2002) 330-336
8. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Proct. 28 (1995) 103-117
9. Gaede P.H., Jepsen P.V., Larsen J.N., et al. The Steno-2 Study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes [in Danish]. Ugeskr Loeger. 165 (2003) 2658-2661
10. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 27 Suppl 1 (2004) S15-S35
11. American Association of Clinical Endocrinologists. Consensus statement on guidelines for glycemic control. Endocrine Proct. 8 Suppl 1 (2002) 40-82
12. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med. 16 (1999) 716-730
13. Muggeo M., Zoppini G., Bonora E., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: The Verona Diabetes Study. Diabetes Care 23 (2000) 45-50
14. Avignon A., Radauceanu A., and Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20 (1997) 1822-1826
15. Verges B. The impact of regulation of postprandial glucose in practice [in French]. Diabetes Metob. 25 Suppl 7 (1999) 22-25
16. Jackson C.A., Yudkin J.S., and Forrest R.D. A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. Diabetes Res Clin Proct. 17 (1992) 111-123
17. Meigs J.B., Nathan D.M., D'Agostino Sr. R.B., Wilson P.W., and Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care 25 (2002) 1845-1850
18. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1 c). Diabetes Care 26 (2003) 881-885
19. Woerle H.J., Pimento W.P., Meyer C., et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. Arch Intern Med. 164 (2004) 1627-1632
20. Yki Jarvinen H., Dressler A., Ziemen M., and HOE 901/3005 Study Group. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 (2000) 1130-1136
21. Owens D.R., Coates P.A., Luzio S.D., et al. Pharmacokinetics of 1251-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23 (2000) 813-819
22. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
23. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
24. Rosenstock J., Schwartz S.L., Clark Jr. C.M., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
25. Fonseca V., Bell D.S., Berger S., et al. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: Subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci. 328 (2004) 274-280
26. Massi Benedetti M., Humburg E., Dressler A., and Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Harm Metob Res. 35 (2003) 189-196
27. Plank J., Bodenlenz M., Sinner F., et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28 (2005) 1107-1112
28. Available at:. Levemir European Public Assessment Report. European Medicines Agency. Accessed October 4, 2006 (2006). http://www.emea.europa.eu/humandocs/Humans/EPAR/levemir/levemir.htm
29. Hoak T., Tiengo A., Draeger E., et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 7 (2005) 56-64
30. Raslova K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes [published correction appears in Diabetes Res Clin Proct. 2006;72: 112]. Diabetes Res Clin Proct. 66 (2004) 193-201
31. Hoffman A., and Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Phormocokinet. 33 (1997) 285-301
32. Becker R.H., Frick A.D., Burger F., et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese, non-diabetic subjects. Exp Clin Endocrinol Diabetes 113 (2005) 435-443
33. Holleman F., and Hoekstra J.B. Insulin lispro [published correction appears in N Engl J Med. 2003;349:1487]. N Engl J Med. 337 (1997) 176-183
34. Home P.D., Barriocanal L., and Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Phormocol. 55 (1999) 199-203
35. Bastyr III E.J., Stuart C.A., Brodows R.G., et al., IOEZ Study Group. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbAl c. Diabetes Care 23 (2000) 1236-1241
36. Perriello G., Pampanelli S., Porcellati F., et al. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: A randomized, stratified, double-blind and cross-over trial. Diabet Med. 22 (2005) 606-611
37. Dailey G., Rosenstock J., Moses R.G., and Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27 (2004) 2363-2368
38. Garg S.K., Rosenstock J., and Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glulisine versus regular human insulin in combination with basal insulin glargine [pub lished correction appears in Endocr Proct. 2005;11:145]. Endocr Proct. 11 (2005) 11-17
39. Feinglos M.N., Thacker C.H., English J., et al. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 20 (1997) 1539-1542
40. Abstract A326-OR. Bretzel R., and Linn T. Equivalence of basal insulin glargine vs prandial insulin lispro for glucose control in type 2 diabetes patients on oral agents-results of the APOLLO study. Diabetes 55 Suppl 1 (2006)
41. Koivisto V.A., Tuominen J.A., and Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22 (1999) 459-462
42. Janka H.U., Plewe G., Riddle M.C., et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
43. Raskin P., Allen E., Hollander P., et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
44. de Boer H., Jansen M., Koerts J., and Verschoor L. Prevention of weight gain in type 2 diabetes requiring insulin treatment. Diabetes Obes Metab. 6 (2004) 114-119
45. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 289 (2003) 2254-2264
46. Emanuele N., Azad N., Abraira C., et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med. 158 (1998) 2485-2490
47. Cusi K., Cunningham G.R., and Comstock J.P. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 18 (1995) 843-851
48. Hermansen K., Davies M., Derezinksi T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
49. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 49 (2006) 442-451
50. Davies M., Storms F., Shutler S., et al., ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algo rithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288
51. Available at:. The OSIRIS Trial. Opposing step-by-step insulin reinforcement to intensified strategy. Accessed October 4 (2006). http://www.clinicaltrials.gov/et/show/NCT00174642
52. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972